Curated News
By: NewsRamp Editorial Staff
May 15, 2025
Silo Pharma Collaborates with Veloxity Labs for Ongoing Study of PTSD Treatment SPC-15
TLDR
- Silo Pharma's partnership with Veloxity Labs for bioanalysis of SPC-15 gives a strategic edge in PTSD treatment development.
- Silo Pharma collaborates with Veloxity Labs for GLP-compliant bioanalysis supporting FDA submission for SPC-15 PTSD treatment.
- Silo Pharma's development of SPC-15 for PTSD treatment shows promise in enhancing mental health therapy options for a better tomorrow.
- Silo Pharma's innovative intranasal treatment SPC-15 for PTSD opens new possibilities in mental health therapeutics.
Impact - Why it Matters
This news matters as it highlights the progress of Silo Pharma in developing innovative treatments for stress-induced psychiatric disorders and chronic pain conditions. The partnership with Veloxity Labs signifies a significant step towards potentially addressing PTSD with the intranasal treatment SPC-15, offering hope for individuals suffering from these conditions.
Summary
Silo Pharma (NASDAQ: SILO) has partnered with Veloxity Labs to conduct GLP-compliant bioanalysis for its ongoing toxicology and toxicokinetics study of SPC-15, an intranasal treatment aimed at preventing PTSD. The data will support an FDA investigational new drug submission expected in 2025. If approved, Silo plans to advance SPC-15 into a Phase 1 human clinical trial.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Silo Pharma Collaborates with Veloxity Labs for Ongoing Study of PTSD Treatment SPC-15
